Boston Scientific analyst cuts highlight growth concerns, shares under pressure

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 09:32.

Boston Scientific (US10117L1017) enters midweek trade on the NYSE with a marked analyst recalibration in focus. Piper Sandler and BTIG have both cut their price targets in June while maintaining positive ratings on the shares, according to recent analyst commentary. Piper Sandler and BTIG updates on Boston Scientific

What the latest analyst notes say

On June 12, Piper Sandler analyst Matt O'Brien lowered his Boston Scientific target from 90 to 65 dollars, roughly 45 percent above the current valuation, and reiterated an Overweight rating. Piper Sandler maintains Overweight with reduced target He cited a marked share decline and slower progress toward management's long-standing goal of at least 10 percent annual revenue growth, emphasizing deceleration in several key metrics in recent quarters. Analyst commentary on growth trajectory

BTIG's Marie Thibault also cut her target from 80 to 65 dollars earlier in June, reaffirming a Buy stance and focusing on more muted expectations for the Watchman heart device franchise over the near term. BTIG pricing and Watchman growth outlook Thibault expects Watchman sales to be broadly flat in the second and third quarters, with only modest quarter-on-quarter improvement in the fourth quarter and a more gradual recovery extending into 2027. Medium-term Watchman sales expectations

How the stock has traded recently

Boston Scientific shares trade on the NYSE under the ticker BSX and closed the latest session at 45.60 dollars, up about 2.86 percent on the day, outpacing a 1.44 percent decline in the S&P 500. Zacks report on Boston Scientific share performance Over the past month, the shares have fallen roughly 23 percent, significantly lagging the broader medical sector's small gain and the S&P 500's near-flat move in the same period. One-month performance versus sector and index

Options data underline heightened positioning in the stock. On June 23, around 78,500 Boston Scientific options contracts changed hands, with open interest near 757,000 contracts, and a put option with a 46 dollar strike for June 26 reportedly seeing about 14,700 contracts traded and turnover of roughly 2.06 million dollars. Moomoo data on recent BSX options activity This elevated options activity suggests active hedging or speculative positioning around current price levels as investors digest the slower growth guidance and revised analyst targets.

The business behind the stock

Boston Scientific generates most of its revenue from minimally invasive medical devices used in cardiology, endoscopy and urology procedures, with key franchises including the Watchman left atrial appendage closure system in structural heart, drug-eluting stents and various electrophysiology catheters. Company overview of Boston Scientific businesses The firm focuses on technologies that help physicians treat cardiovascular disease, rhythm disorders and other conditions through catheter-based interventions rather than open surgery, which underpins recurring demand as global procedure volumes grow.

Where the shares trade today

Boston Scientific shares (US10117L1017) trade on the NYSE at 45.60 dollars as of 2026-06-24, 09:30, placing the company's equity value clearly below recent analyst targets and reflecting the more cautious near-term growth outlook embedded in recent research commentary.

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any securities. All data are based on sources believed to be reliable but may be subject to change.